NASH and post-transplant metabolic syndrome
The presence or recurrence of metabolic syndrome following liver transplantation can contribute to the development and recurrence of NAFLD in the liver allograft...
Commented Articles
PanNASH covers commented articles ans publications to acquire sufficient information, understanding, and skills to cope with NASH/NAFLD healthcare demands.
Read MoreNASH and post-transplant metabolic syndrome
Insulin resistance in MAFLD
Many studies have reported that metabolic dysfunction is closely involved in the complex mechanism underlying the development of NAFLD. This has prompted a movement to consider renaming NAFLD as metabolic dysfunction-associated fatty liver disease...
NATIVE: first clinical trial demonstrating…
Treatment options for NASH are limited. S. M. Francque et al. (Antwerp University Hospital, Belgium) examined the effects of lanifibranor, a pan-agonist of the peroxisome proliferator–activated receptors with favourable effects on glucose and lipid metabolism, inflammation, and fibrosis, in 247 patients with active, noncirrhotic NASH...
Lanifibranor in NASH: NATiV3, an ongoing phase 3 trial
The New England Journal of Medicine has published the results of the NATIVE Phase IIb clinical trial with lanifibranor in NASH. Lanifibranor met both the primary and key secondary endpoints, including NASH resolution with no worsening of fibrosis and improvement of liver fibrosis with no worsening of NASH...
Outcomes in adults with NAFLD
Given the growing importance of NAFLD and its inflammatory manifestation, in a new prospective study from the NASH Clinical Research Network, A. J. Sanyal et al. describe outcomes for 1773 adults with biopsy-proven NAFLD with an average follow-up period of 4 years...
New targets for NAFLD
NAFLD is a growing cause of chronic liver disease worldwide. Several preclinical models (dietary and genetic animal models) of NAFLD have deepened our understanding of its aetiology and pathophysiology. Despite the progress made, there are currently no effective treatments for NAFLD...
NAFLD and incident dementia in elderly patients
An association between NAFLD and brain aging has been suggested. Therefore, C. Labenz et al. aimed to investigate the hypothesis if NAFLD is an independent risk factor for emerging dementia...
Obese NAFLD children and adolescents: high BMI predicts liver fibrosis
H. Moran-Lev et al. (Dana Dwek Children’s Hospital, Tel Aviv University, Israel) aimed to investigate the predictors for liver fibrosis and the effects of short-term nutritional intervention on steatosis and fibrosis among obese adolescents with NAFLD...
NAFLD in the elderly
The diagnosis and management strategies of NAFLD in older adults are sometimes challenging, and certain age-specific factors have to be taken into account. In this review, S. A. Alqahtani (King Faisal Specialist Hospital & Research Center, Saudi Arabia and Johns...
NAFLD and incident chronic kidney disease
The association of NAFLD and CKD has been established before. The aim of this large-scale database study was to investigate the role of NAFLD on emerging CKD, the emergence of end-stage renal disease and the identification of additional risk factors which may increase the risk for CKD in Germany...
Hepatocellular carcinoma diagnosis and quality of life
M. Verma et al. (Inova Fairfax Medical Campus, Inova Health System, USA) aimed to compare hepatocellular cancer cases with matched controls to evaluate the differences in change in quality of life from before to after hepatocellular cancer diagnosis, using the Medical Outcomes Study Short Form-36...
Diabetic kidney disease, cardiovascular disease and NAFLD
NAFLD, cardiovascular disease and chronic kidney disease share a common pathophysiology including insulin resistance, oxidative stress, chronic inflammation, dysbiosis and genetic susceptibilities. The aim of this review by C. M. Perdomo et al...